SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Hemispherx Biopharma of Upcoming Deadline - HEB

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Hemispherx
Biopharma of Upcoming Deadline - HEB

NEW YORK, Jan. 25, 2013 (GLOBE NEWSWIRE) -- Pomerantz Grossman Hufford
Dahlstrom & Gross LLP has filed a class action lawsuit against Hemispherx
Biopharma, Inc. ("Hemispherx" or the "Company") (NYSE:HEB) and certain of its
officers. The class action filed in United States District Court, Eastern
District of Pennsylvania, on behalf of a class consisting of all persons or
entities who purchased or otherwise acquired securities of Hemispherx between
March 22, 2012 and December 17, 2012, both dates inclusive (the "Class
Period"). This class action seeks to recover damages against the Company and
certain of its officers and directors as a result of alleged violations of the
federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Hemispherx securities during the Class
Period, you have until February 19, 2013 to ask the Court to appoint you as
Lead Plaintiff for the class. A copy of the Complaint can be obtained at
www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237.
Those who inquire by e-mail are encouraged to include their mailing address
and telephone number.

Hemispherx is a biopharmaceutical company that focuses on the development of
nucleic acids to enhance the natural anti-viral defense systems of the human
body. The Company's lead product, AmpligenĀ® ("Ampligen"), is undergoing
clinical trials for the treatment of Myalgic Encephalomylitis/Chronic Fatigue
Syndrome.

The Complaint alleges that throughout the Class Period, the Company made a
host of materially false and misleading statements regarding the safety and
efficacy of Ampligen, and touted purportedly positive results from Ampligen's
clinical trials. As a result of the foregoing, the Company's statements were
materially false and misleading at all relevant times.

On December 18, 2012, the FDA published an FDA staff report concerning
Ampligen's safety and efficacy. Specifically, the report concluded that the
Company's studies were "ill-defined and invalid" with signals of efficacy that
were inconsistent between clinical trials, and based on the limited quality of
the data, "it is difficult to draw conclusions regarding potential safety
signals," but the "review identified nine potential safety concerns associated
with Ampligen."

As a result of this disclosure, Hemispherx shares declined $0.276 per share or
nearly 43%, to close at $0.368 per share on December 18, 2012.

As a result of Company's wrongful acts and omissions, and the precipitous
decline in the market value of the Company's securities, Class members have
suffered significant damages.

The Pomerantz Firm, with offices in New York, Chicago, and San Diego, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. Willoughby
         Pomerantz Grossman Hufford Dahlstrom & Gross LLP
         rswilloughby@pomlaw.com